Menu
← Oncology Approval Tracker
FDA DECISION ·
Tecentriq Hybreza
atezolizumab and hyaluronidase-tqjs · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous use for adult indications shared with IV atezolizumab, including specified lung, liver, melanoma and alveolar soft part sarcoma indications.
LAMPGEN ANALYSIS
Why it matters
The formulation adds a subcutaneous route, with a bridging study in previously treated non-small cell lung cancer.
What research teams should watch
Separate IV and subcutaneous orders, and confirm the indication and any combination partners before a route change.
PRIMARY RECORDS